One of the FDA’s recently departed top officials is weighing in on the wide-ranging staff cuts at the agency and how they ...

Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID ...

Health secretary Robert F. Kennedy Jr. has expressed another unorthodox view on vaccines, declaring that single antigen ...

The decline in Novavax stock follows the HHS Secretary's concerns regarding the efficacy of its protein-based COVID-19 ...

After the gutting of the Department of Health and Human Services, fears mount about the future direction of the FDA—with ...

In the wake of unprecedented workforce cuts at the FDA, former Commissioner Scott Gottlieb and an unnamed former CBER ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

Dr. Peter Marks, an ex-FDA vaccine official, is warning of a fundamental change at the agency—where vaccine skepticism now ...

The former top vaccines official at the Food and Drug Administration criticized Health and Human Services Secretary Robert F.

When asked if the delay resulted from "personnel being shuffled" at the FDA, Kennedy attributed it to the vaccine's ...

The FDA missed the April 1 regulatory decision target date for Novavax’s Covid-19 vaccine. Politico reported the holdup was due to the intervention of Sara Brenner, the FDA’s principal deputy ...

An advisory panel on vaccines meets, carefully, in the shadow of a health secretary who has often criticized it.